Key Points
- CFO Shawn Cross sold 15,896 shares on Dec. 9 at an average price of $25.03 (≈$397,877) and an additional 9,104 shares on Dec. 10, leaving him with 56,250 shares — a 22.03% reduction in his ownership.
- Pacira (NASDAQ:PCRX) has a market cap of about $1.11B, reported $0.70 EPS (beating estimates) while revenue slightly missed expectations, and holds a consensus analyst rating of "Hold" with a $28.20 price target.
Pacira BioSciences, Inc. (NASDAQ:PCRX - Get Free Report) CFO Shawn Cross sold 9,104 shares of the firm's stock in a transaction dated Wednesday, December 10th. The shares were sold at an average price of $25.14, for a total transaction of $228,874.56. Following the completion of the transaction, the chief financial officer directly owned 56,250 shares in the company, valued at $1,414,125. This trade represents a 13.93% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at the SEC website.
Shawn Cross also recently made the following trade(s):
- On Tuesday, December 9th, Shawn Cross sold 15,896 shares of Pacira BioSciences stock. The stock was sold at an average price of $25.03, for a total transaction of $397,876.88.
Pacira BioSciences Price Performance
PCRX opened at $25.83 on Friday. The company has a fifty day moving average price of $23.11 and a two-hundred day moving average price of $24.15. The firm has a market capitalization of $1.11 billion, a PE ratio of 57.44 and a beta of 0.23. Pacira BioSciences, Inc. has a 52 week low of $18.17 and a 52 week high of $27.64. The company has a debt-to-equity ratio of 0.52, a quick ratio of 3.78 and a current ratio of 5.26.
Pacira BioSciences (NASDAQ:PCRX - Get Free Report) last posted its quarterly earnings results on Thursday, November 6th. The company reported $0.70 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.65 by $0.05. The business had revenue of $179.52 million for the quarter, compared to analyst estimates of $182.86 million. Pacira BioSciences had a return on equity of 12.82% and a net margin of 2.99%.The firm's revenue was up 6.5% on a year-over-year basis. During the same period last year, the company earned $0.79 EPS. As a group, analysts anticipate that Pacira BioSciences, Inc. will post 2.41 earnings per share for the current year.
Institutional Investors Weigh In On Pacira BioSciences
Institutional investors have recently bought and sold shares of the company. Hantz Financial Services Inc. boosted its position in Pacira BioSciences by 175.4% during the 3rd quarter. Hantz Financial Services Inc. now owns 1,132 shares of the company's stock worth $29,000 after acquiring an additional 721 shares during the last quarter. Caitong International Asset Management Co. Ltd acquired a new position in Pacira BioSciences during the first quarter worth $51,000. US Bancorp DE grew its position in Pacira BioSciences by 31.0% in the first quarter. US Bancorp DE now owns 2,270 shares of the company's stock valued at $56,000 after purchasing an additional 537 shares in the last quarter. Brooklyn Investment Group grew its position in Pacira BioSciences by 372.2% in the first quarter. Brooklyn Investment Group now owns 2,238 shares of the company's stock valued at $56,000 after purchasing an additional 1,764 shares in the last quarter. Finally, Tidemark LLC acquired a new stake in Pacira BioSciences in the 3rd quarter valued at $56,000. Institutional investors own 99.73% of the company's stock.
Analyst Upgrades and Downgrades
A number of analysts recently weighed in on the stock. Weiss Ratings reiterated a "sell (d+)" rating on shares of Pacira BioSciences in a research report on Monday. Zacks Research upgraded shares of Pacira BioSciences from a "strong sell" rating to a "hold" rating in a report on Thursday, August 14th. Truist Financial reduced their price target on shares of Pacira BioSciences from $30.00 to $28.00 and set a "buy" rating on the stock in a research report on Friday, November 7th. Wall Street Zen raised Pacira BioSciences from a "buy" rating to a "strong-buy" rating in a research note on Saturday, November 8th. Finally, Barclays assumed coverage on Pacira BioSciences in a report on Tuesday. They set an "equal weight" rating and a $27.00 target price on the stock. Three investment analysts have rated the stock with a Buy rating, three have assigned a Hold rating and one has assigned a Sell rating to the company's stock. According to MarketBeat.com, the stock presently has a consensus rating of "Hold" and a consensus price target of $28.20.
View Our Latest Research Report on Pacira BioSciences
Pacira BioSciences Company Profile
(
Get Free Report)
Pacira Biosciences, Inc is a holding company, which engages in the provision of non-opioid pain management and regenerative health solutions to improve patients' journeys along the neural pain pathway. Its products include EXPAREL, iovera, and DepoFoam. The company was founded in December 2006 and is headquartered in Tampa, FL.
Read More
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
